Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Tezspire tezepelumab Asthma Reimburse with clinical criteria and/or conditions Complete
Thelin Sitaxsentan sodium Pulmonary arterial hypertension (WHO class II and III) Do not list Complete
Thelin Sitaxsentan sodium Pulmonary arterial hypertension (WHO class II and III) Do not list Complete
Tibsovo ivosidenib Acute myeloid leukemia (AML) Reimburse with clinical criteria and/or conditions Active
Tivicay Dolutegravir HIV infection List Complete
Toctino Alitretinoin Eczema List with clinical criteria and/or conditions Complete
Toviaz Fesoterodine fumarate Overactive bladder List in a similar manner Complete
Trajenta Linagliptin Diabetes mellitus, type 2 List with clinical criteria and/or conditions Complete
Tramacet Tramadol hydrochloride /acetaminophen Acute pain Do not list Complete
Translarna ataluren Cancelled